Corona Remedies Limited has announced an expansion of manufacturing capacity at its Bhayla formulation facility to support rising demand for its products. The expansion will add 400 million units of tablet and capsule capacity, with 240 million units expected to be available for utilisation. The increased capacity is scheduled to become operational from December 22, 2025.

The company said the expansion will be funded entirely through internal accruals and is part of its strategy to strengthen in-house manufacturing capabilities and enhance supply reliability. As of March 31, 2025, the Bhayla facility was operating at a capacity utilisation level of approximately 93.6 percent, underscoring the need for additional capacity.

With the expansion, Corona Remedies aims to improve operational flexibility and ensure timely supply across its key therapeutic segments. The company operates as a branded pharmaceutical formulations player in India, with a focus on women’s healthcare, cardio-diabetes, pain management, urology and other specialty segments. Its manufacturing facilities comply with global quality standards, including WHO-GMP and EU-GMP certifications.